StemCells, an age-related macular degeneration drug researcher, received FDA to start a clinical trial on the potential treatment for dry age-related macular degeneration, according to a news release.
The trial will evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. These cells are a purified population of human neural stem cells that can self-renew and differentiate into the three major cell types. Currently, there is no approved treatment for dry AMD.
Related Articles on Ophthalmology:
Ophthalmologists Have More Musculoskeletal Disorders Than Other Physicians
Researchers Find Simple Surgery Fixes Crossed Eyes
FDA Approves Mobius Therapeutics' Glaucoma Drug
The trial will evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. These cells are a purified population of human neural stem cells that can self-renew and differentiate into the three major cell types. Currently, there is no approved treatment for dry AMD.
Related Articles on Ophthalmology:
Ophthalmologists Have More Musculoskeletal Disorders Than Other Physicians
Researchers Find Simple Surgery Fixes Crossed Eyes
FDA Approves Mobius Therapeutics' Glaucoma Drug